Webinar: Early-Life Microbiome: The Hidden Architect of Neuroimmune Health

Early-Life Microbiome: The Hidden Architect of Neuroimmune Health

/upload/webinar-3-pdduet.jpg

Join Biotrend and Elabscience for a webinar exploring how the early-life gut microbiome is increasingly recognized as a key modulator of neuroimmune development and long-term health. We’ll review cohort evidence, mechanistic pathways, translational biomarkers, and the latest microbiome-targeted interventions to help you design rigorous translational studies.

Date: December 9, 2025
Time: 11 AM CET

Overview

The first 1,000 days are a critical window during which microbial colonization and environmental exposures shape immune programming and neurodevelopment. Longitudinal and mechanistic studies identify microbial metabolites and immune mediators as plausible links between early dysbiosis and later risks for immunologic and neurodevelopmental outcomes; however, human findings vary across cohorts and remain actively investigated.

Gut–Brain–Immune Axis

Microbial metabolites, enteric nervous system signaling, and microglial priming.

Recent Cohort Insights

Key cohort and multi-omics insights (GEMMA, TEDDY, and others) and their translational implications.

Long-Term Dysbiosis Effects

Mechanistic evidence linking LPS and other microbial products to blood–brain barrier and neuroinflammation (primarily experimental data).

Therapeutic Interventions

Pre-, Pro-, and Postbiotics, dietary modulation, and evolving preclinical/early-phase clinical microbiome interventions.

Precision Tools from Elabscience®

Cytokine ELISAs to quantify immune signaling (e.g., Human IL-6 ELISA — sensitivity ~0.94 pg/mL; detection range 1.56–100 pg/mL).
Oxidative Stress Assay Kits for inflammation-linked neuronal damage.
Gut microbiota biomarker kits (e.g., LPS ELISA — sensitivity ~9.4 pg/mL) for assessing barrier permeability/systemic translocation in translational studies. Confirm matrix validation with vendor for CSF or fecal water.

Meet the Speaker

Dr. Sundas R. Qureshi

Business Development Scientist, Elabscience Bionovation, Inc.

Dr. Sundas R. Qureshi is an innovative scientist and accomplished business leader with more than 12 years of experience in biotechnology, cell biology, immunology, and entomology. She has delivered over 150 international technical training sessions covering cell culture, flow cytometry, immunology methods, cell health, and metabolism. Combining expertise in immunology, protein research, and entomology, she effectively connects research and industry. Dr. Qureshi is dedicated to driving scientific innovation, supporting emerging researchers, and collaborating with experts to advance biotechnology globally.

Key Takeaways

Critical Window

Early-life microbiome as a modifiable determinant of neuroimmune resilience (association, not proven causal in humans).

Biomarker Validation

Practical biomarker and assay choices for translational cohorts.

Therapeutic Pipeline

How to design intervention-focused research with realistic expectations about evidence strength.

Secure your spot: Tuesday, December 9, 2025, at 11 AM CET